Andrea Brioschi MD

Publications (1)4.51 Total impact

• Article: Transdermal apomorphine permeation from microemulsions: A new treatment in Parkinson's disease

  Lorenzo Priano MD, Gianni Albani MD, Andrea Brioschi MD, Sara Calderoni, PhD Leonardo Lopiano MD, Mario Rizzone MD, Roberta Cavalli PhD, Maria Rosa Gasco PhD, PhD Francesco Scaglione MD, Franco Fraschini PhD, [......], Gianni Albani, Andrea Brioschi, Leonardo Lopiano, Mario Rizzone, Roberta Cavalli, Maria Rosa Gasco, Francesco Scaglione, Franco Fraschini, Bruno Bergamasco, Alessandro Mauro
  [show abstract] [hide abstract]
  ABSTRACT: We studied absorption, efficacy, and tolerability in Parkinson's disease (PD) of a new preparation of apomorphine included in a microemulsion and administered by transdermal route (Apo-MTD). Twenty-one PD patients were treated with levodopa plus oral dopamine-agonists (T0), with levodopa alone (T1), finally with levodopa plus Apo-MTD (T2). Apo-MTD provided therapeutic plasma levels for many hours, improved Unified Parkinson's Disease Rating Scale III scores, and reduced total duration of off periods compared to T0 and T1. We concluded that Apo-MTD is absorbed and demonstrates clinical efficacy and long action. Therefore, it seems a promising add-on treatment for uncontrolled prolonged off phases in PD patients, but chronic tolerability needs further study. © 2004 Movement Disorder Society
  Movement Disorders 07/2004; 19(8):937 - 942. · 4.51 Impact Factor